J&J's device unit "weak" in Q3
This article was originally published in Clinica
Executive Summary
Although Johnson & Johnson’s overall third quarter was “solid,” growth in its medical devices and diagnostics (MD&D) division “remains weak,” according to Morgan Stanley analyst David Lewis. Sales in the latter fell 2% to $6.9bn, while group revenues were up 3% to $17.6bn, boosted by “particularly strong results” in its pharma division (where sales grew 10%).